JBSNF-000088

What is JBSNF-000088 ?

JBSNF-000088 is a naturally occurring metabolite derived from nicotinamide (Vitamin B3) through the enzymatic action of Nicotinamide N-Methyltransferase (NNMT). Initially studied in the context of cancer metabolism, where its precursor nicotinamide is methylated by NNMT and cleared from cells, research has unveiled a more complex and beneficial role for 6-MNA itself. Unlike direct NAD+ precursors like NMN or Nicotinamide Riboside (NR), which primarily function by boosting cellular NAD+ levels to enhance energy metabolism and activate sirtuins, 6-MNA operates through an alternative pathway. It acts as a potent and selective inhibitor of the enzyme poly(ADP-ribose) polymerase-1 (PARP-1). While PARP-1 is crucial for DNA repair, its over-activation, often driven by chronic oxidative stress, can excessively deplete cellular NAD+ pools, leading to energy crisis and cellular senescence. By moderately inhibiting PARP-1, 6-MNA helps conserve NAD+, thereby promoting mitochondrial function and cellular resilience without compromising essential DNA repair mechanisms.

• Inhibits NNMT: JBSNF-000088 acts as a slow-turnover substrate analog, binding to and inhibiting the NNMT enzyme.
• Reduces MNA levels: By inhibiting NNMT, it lowers the concentration of MNA, a metabolite linked to obesity and insulin resistance.
• Improves insulin sensitivity: In animal models of diet-induced obesity, treatment with JBSNF-000088 improved insulin sensitivity.
• Reduces body weight: It caused a reduction in body weight in mice with high-fat diet-induced obesity.
• Normalizes glucose tolerance: JBSNF-000088 normalized glucose tolerance in these mice to the level of lean control mice.
• Specificity confirmed: The effects of JBSNF-000088 were not observed in NNMT knockout mice, confirming that its metabolic benefits are specifically due to NNMT inhibition.

• Obesity and Type 2 Diabetes: High NNMT expression is linked to obesity and type 2 diabetes. JBSNF-000088 has been shown in mouse models to reduce body weight, improve glucose tolerance, and increase insulin sensitivity.
• General metabolic disease: JBSNF-000088 is being explored as a treatment for a range of metabolic disorders.

You can contact us directly or send me email :  sales8@bpandabio.com

The market outlook for JBSNF-000088 is promising but intertwined with the dynamics of the broader longevity and dietary supplement industry.

Positioning in the Competitive Longevity Space:JBSNF-000088 is poised to be a premium, mechanism-driven ingredient. It is not a direct competitor to NMN or NR but rather a complementary agent that targets a different node in the NAD+ metabolism network. Its unique value proposition lies in its dual action of conserving NAD+ via PARP-1 inhibition and boosting antioxidant defenses via Nrf2 activation.

Driven by Scientific Validation and Premiumization: The market success of JBSNF-000088 will heavily depend on continued high-quality scientific research, particularly robust human clinical trials. Positive results will allow it to be marketed as a scientifically-backed, next-generation longevity supplement, commanding a higher price point.

Regulatory Landscape and Formulation Synergy: As a dietary supplement ingredient, its regulatory pathway is clearer than for pharmaceuticals. We can expect to see JBSNF-000088 incorporated into sophisticated supplement formulations, combined with other proven ingredients like NMN, resveratrol, or senolytics to create synergistic "longevity stacks" that target multiple aging pathways simultaneously.

Challenges and Opportunities: A key challenge will be educating consumers on its complex mechanism compared to the simpler "boosting NAD+" narrative. However, this also presents an opportunity to attract a more sophisticated consumer base. The global anti-aging market's continued expansion ensures a ready and growing audience for innovative solutions like JBSNF-000088.

Hot Tags: jbsnf-000088, China jbsnf-000088 manufacturers, suppliers, factory, Daidzein Powder, API